Catalyst Study Advances Carbon-Dioxide-to-Ethanol Conversion

Researchers: Majority of patients with Alzheimer’s disease would not have been eligible for clinical trials of new controversial Alzheimer’s drug    

• share
• favorite_border

Beth Israel Lahey Health

In a research letter in JAMA, physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) found that the vast majority of patients who had a diagnosis of either cognitive impairment, Alzheimer’s disease, or Alzheimer’s disease related disorders, including cardiovascular disease, prior stroke, use of blood thinners, and age over 85 years, would have been excluded them from the aducanumab clinical trials.

Research Results
MEDICINE